{"id":181576,"date":"2024-01-28T14:22:30","date_gmt":"2024-01-28T20:22:30","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/01\/crispr-off-switches-a-path-towards-safer-genome-engineering"},"modified":"2024-01-28T14:22:30","modified_gmt":"2024-01-28T20:22:30","slug":"crispr-off-switches-a-path-towards-safer-genome-engineering","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/01\/crispr-off-switches-a-path-towards-safer-genome-engineering","title":{"rendered":"CRISPR off-switches: A path towards safer genome engineering?"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/crispr-off-switches-a-path-towards-safer-genome-engineering2.jpg\"><\/a><\/p>\n<p>Using CRISPR, an immune system bacteria use to protect themselves from viruses, scientists have harnessed the power to edit genetic information within cells. In fact, the first CRISPR-based therapeutic was recently approved by the FDA to treat sickle cell disease in December 2023. That therapy is based on a highly studied system known as the CRISPR-Cas9 genetic scissor.<\/p>\n<p>However, a newer <a href=\"https:\/\/phys.org\/news\/2022-01-discovery-hidden-gem-enables-gene.html\">and unique platform with the potential to make large-sized DNA removals<\/a>, called Type I CRISPR or CRISPR-Cas3, waits in the wings for potential therapeutic use.<\/p>\n<p>A new study from Yan Zhang, Ph.D., Assistant Professor in the Department of Biological Chemistry at the University of Michigan Medical School, and her collaborators at Cornell University develops off-switches useful for improving the safety of the Type I-C\/Cas3 gene editor. The study, \u201cExploiting Activation and Inactivation Mechanisms in Type I-C CRISPR-Cas3 for 3 Genome Editing Applications,\u201d is <a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1097276523010808\">published<\/a> in the journal Molecular Cell.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Using CRISPR, an immune system bacteria use to protect themselves from viruses, scientists have harnessed the power to edit genetic information within cells. In fact, the first CRISPR-based therapeutic was recently approved by the FDA to treat sickle cell disease in December 2023. That therapy is based on a highly studied system known as the [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11,412],"tags":[],"class_list":["post-181576","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/181576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=181576"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/181576\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=181576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=181576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=181576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}